Study reveals that APS (200 mg/kg) treatment increases weight and colon length and reduces NF-κB DNA phosphorylation activity and down-regulates TNF-α, IL-1β, IL-6, IL-17 expressions associated with improvement in DSS-induced mice colitis [116]. This evidence concerns the gene NFKB1 and colitis.